Patents by Inventor Josef Endl
Josef Endl has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230399396Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of TL-2 and TL-21.Type: ApplicationFiled: August 11, 2022Publication date: December 14, 2023Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
-
Publication number: 20210062149Abstract: Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG+CD19+-B-cells, IgG+CD38+-B-cells, IgG+CD268+-B-cells, IgG?CD138+-B-cells, CD27+CD138+-B-cells or CD3?CD27+-B-cells. The method can comprise the step of incubating said B-cells at 37° C. for one hour in EL-4 B5 medium prior to the depositing step. The method can also comprise the step of centrifuging said single cell deposited B-cells prior to the co-cultivation. In the co-cultivation a feeder mix comprising interleukin-1beta, and tumor necrosis factor alpha and Staphylococcus aureus strain Cowans cells or BAFF or interleukin-2 and/or interleukin-10 and/or interleukin-6 and/or interleukin-4 can be used.Type: ApplicationFiled: June 12, 2020Publication date: March 4, 2021Applicant: Hoffmann-La Roche Inc.Inventors: Josef ENDL, Natalie SCHUHMACHER, Sonja OFFNER, Josef PLATZER, Basile SIEWE, Irmgard THOREY
-
Publication number: 20190153091Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.Type: ApplicationFiled: October 3, 2018Publication date: May 23, 2019Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
-
Publication number: 20180298335Abstract: Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG+CD19+-B-cells, IgG+CD38+-B-cells, IgG+CD268+-B-cells, IgG?CD138+-B-cells, CD27+CD138+-B-cells or CD3?CD27+-B-cells. The method can comprise the step of incubating said B-cells at 37° C. for one hour in EL-4 B5 medium prior to the depositing step. The method can also comprise the step of centrifuging said single cell deposited B-cells prior to the co-cultivation. In the co-cultivation a feeder mix comprising interleukin-1beta, and tumor necrosis factor alpha and Staphylococcus aureus strain Cowans cells or BAFF or interleukin-2 and/or interleukin-10 and/or interleukin-6 and/or interleukin-4 can be used.Type: ApplicationFiled: March 27, 2018Publication date: October 18, 2018Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Natalie Schuhmacher, Sonja Offner, Josef Platzer, Basile Siewe, Irmgard Thorey
-
Publication number: 20160251621Abstract: Herein is reported a method for obtaining a B-cell comprising the following steps a) labeling B-cells, b) depositing the labeled B-cells as single cells, c) co-cultivating the single cell deposited B-cells with feeder cells, d) selecting a B-cell proliferating and secreting IgG in step c) and thereby obtaining a B-cell. The labeling can be of IgG+CD19+-B-cells, IgG+CD38+-B-cells, IgG+CD268+-B-cells, IgG?CD138+-B-cells, CD27+CD138+-B-cells or CD3?CD27+-B-cells. The method can comprise the step of incubating said B-cells at 37° C. for one hour in EL-4 B5 medium prior to the depositing step. The method can also comprise the step of centrifuging said single cell deposited B-cells prior to the co-cultivation. In the co-cultivation a feeder mix comprising interleukin-1beta, and tumor necrosis factor alpha and Staphylococcus aureus strain Cowans cells or BAFF or interleukin-2 and/or interleukin-10 and/or interleukin-6 and/or interleukin-4 can be used.Type: ApplicationFiled: May 6, 2016Publication date: September 1, 2016Applicant: Hoffmann-La Roche Inc.Inventors: Josef Endl, Natalie Schuhmacher, Sonja Offner, Josef Platzer, Basile Siewe, Irmgard Thorey
-
Publication number: 20140315252Abstract: Herein is reported a co-cultivation system for co-cultivating a pool of rabbit B-cells or single deposited rabbit B-cells wherein cells CD40L expressing CHO cells are used as feeder in the presence of IL-2 and IL-21.Type: ApplicationFiled: November 21, 2012Publication date: October 23, 2014Inventors: Josef Endl, Jens Fischer, Peter Kern, Sonja Offner, Josef Platzer, Stefan Seeber
-
Patent number: 8541204Abstract: The current invention describes a nucleic acid comprising in a 5? to 3? direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5? splice donor site and terminated by a 3? splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.Type: GrantFiled: December 5, 2012Date of Patent: September 24, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Josef Endl, Erhard Kopetzki, Oliver Ploettner, Ursula Schwarz, Georg Tiefenthaler
-
Patent number: 8354516Abstract: The current invention describes a nucleic acid comprising in a 5? to 3? direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5? splice donor site and terminated by a 3? splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.Type: GrantFiled: May 15, 2007Date of Patent: January 15, 2013Assignee: Hoffmann-La Roche Inc.Inventors: Josef Endl, Erhard Kopetzki, Oliver Ploettner, Ursula Schwarz, Georg Tiefenthaler
-
Publication number: 20110086026Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.Type: ApplicationFiled: July 26, 2010Publication date: April 14, 2011Inventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Patent number: 7807158Abstract: The instant specification discloses an antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of this antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9, and this antibody is useful in the treatment of asthma and allergic diseases.Type: GrantFiled: January 3, 2006Date of Patent: October 5, 2010Assignee: Roche Palo Alto LLCInventors: Josef Endl, Maria Elena Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Thomas Regula, Ralf Schumacher, Stefan Seeber, Jan Olaf Stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Publication number: 20090311725Abstract: The current invention describes a nucleic acid comprising in a 5? to 3? direction a) a first nucleic acid encoding a heterologous polypeptide without an in frame stop codon, b) a second nucleic acid beginning with a 5? splice donor site and terminated by a 3? splice acceptor site comprising an in frame translational stop codon and a polyadenylation signal, and c) a nucleic acid encoding i) at least a fragment of a transmembrane domain, or ii) a signal peptide for a GPI-anchor.Type: ApplicationFiled: May 15, 2007Publication date: December 17, 2009Inventors: Josef Endl, Erhard Kopetzki, Oliver Ploettner, Ursula Schwarz, Georg Tiefenthaler
-
Publication number: 20060263356Abstract: An antibody binding to IL-13R?1, inhibiting IL-13 bioactivity and comprising a variable heavy and a variable light chain, characterized in that the variable heavy chain amino acid sequence CDR3 of said antibody is selected from the group consisting of the heavy chain CDR3 sequences of SEQ ID NO: 1, 3, 5, 7 or 9 is useful in the treatment of asthma and allergic diseases.Type: ApplicationFiled: January 3, 2006Publication date: November 23, 2006Inventors: Josef Endl, Maria Fuentes, Yvo Graus, Adelbert Grossmann, Sebastian Neumann, Paul Parren, Frank Rebers, Joerg Regula, Ralf Schumacher, Stefan Seeber, Jan stracke, Kay-Gunnar Stubenrauch, Jan Van De Winkel, Martine Van Vugt, Sandra Vereecken-Verploegen
-
Publication number: 20060171954Abstract: The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.Type: ApplicationFiled: April 5, 2006Publication date: August 3, 2006Applicant: Roche Diagnostics GmbHInventors: Josef Endl, Peter Stahl, Winfried Albert, Guenther-Gerhard Jung, Dolores Schendel, Edgar Meinl, Klaus Dornmair
-
Patent number: 7064190Abstract: The invention concerns autoreactive peptides, peptide-MHC complexes, T cell subpopulations that react thereto as well as diagnostic and therapeutic applications of these compounds.Type: GrantFiled: November 16, 1999Date of Patent: June 20, 2006Assignee: Roche Diagnostics GmbHInventors: Josef Endl, Peter Stahl, Winfried Albert, Guenther-Gerhard Jung, Dolores J. Schendel, Edgar Meinl, Klaus Dornmair
-
Patent number: 6967108Abstract: The invention concerns human monoclonal antibodies to the islet cell antigen IA-2, a process for their production, the use of human monoclonal antibodies in a method for detecting antibodies to IA-2, a method for detecting antibodies to the islet cell antigen IA-2 and a method for detecting the islet cell antigen IA-2 in a sample.Type: GrantFiled: August 27, 1999Date of Patent: November 22, 2005Assignee: Roche Diagnostics Operations Inc.Inventors: Josef Endl, Thomas Wild, Suzanne Elisabeth Berlo, Verena Litty
-
Publication number: 20020114816Abstract: the invention concerns autoreactive peptides, peptide MHC complexes, t cell subpopulations which react therewith as well as diagnostic and therapeutic applications of these compounds.Type: ApplicationFiled: September 18, 1998Publication date: August 22, 2002Inventors: JOSEF ENDL, PETER STAHL, WINFRIED ALBERT, DOLORES SCHENDEL, CHRISTIAN BOITARD, PETER VAN ENDERT, GUNTHER-GERHARD JUNG
-
Patent number: 6214568Abstract: The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc &ggr; and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.Type: GrantFiled: July 29, 1998Date of Patent: April 10, 2001Assignee: Roche Diagnostics GmbHInventors: Josef Endl, Michael Brandt, Herbert Jungfer, Winfried Albert, Rosemarie Kientsch-Engel, Werner Scherbaum, Wiltrud Richter, Thomas Eiermann
-
Patent number: 5888813Abstract: The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc .gamma. and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells.The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.Type: GrantFiled: November 7, 1995Date of Patent: March 30, 1999Assignee: Boehringer Mannheim GmbHInventors: Josef Endl, Michael Brandt, Herbert Jungfer, Winfried Albert, Rosemarie Kientsch-Engel, Werner Scherbaum, Wiltrud Richter, Thomas Eiermann
-
Patent number: 5610280Abstract: The present invention provides a human monoclonal antibody against melanoma, characterized in that it binds to the gangliosides GM3 and GD3 but essentially does not bind to the gangliosides GM1, GM2, GD1a, GD1b and GD2, the binding of the antibody to the gangliosides having been determined by immune staining after thin layer chromatographic separation of the gangliosides. The present invention also provides a process for the production of human monoclonal antibodies directed against melanoma, wherein, without previous immunization, B-lymphocytes are isolated from a healthy person, the isolated B-lymphocytes are immortalized, antibodies from the immortalized B-lymphocytes are screened by immune-histochemical analysis for binding against melanoma and/or melanoma metastases, the positively reacting B-lymphocytes are selected, cultured and monoclonal antibodies obtained therefrom.Type: GrantFiled: March 15, 1994Date of Patent: March 11, 1997Assignee: Boehringer Mannheim GmbHInventors: Michael Brandt, Josef Endl, Herbert Jungfer, Winfried Albert
-
Process for the quantification of cell populations or subpopulations and a reagent suitable therefor
Patent number: 5094940Abstract: A process for quantification of cell populations or subpopulations, by incubating a sample with labelled antibodies directed against characteristic surface antigens of the cell population to be quantified to form labelled antibody/antigen complexes. Standards with known, differing particle concentration and having comparable sedimentation behaviour to the cells to be determined and further, carrying molecules which are directed against the labelled antibody or a part hereof are also incubated with the labelled antibodies. The cells of the sample solution, as well as the particles of the standard solution, are separated off from the excess labelled antibodies and the amount of the labelling is measured not only on the cells but also on the particles. By comparison of the measurement value from the sample with the measurement values from the standard solutions, there is ascertained the number of cells to be determined in the sample.Type: GrantFiled: July 7, 1989Date of Patent: March 10, 1992Assignee: Boehringer Mannheim GmbHInventors: Hartmut Schetters, Josef Endl, Winfried Albert